Ling Zhang

Dr. Zhang is leading the strategic planning and implementation of the clinical development plans at InventisBio. He has about 20 years of oncology clinical development experience covering small molecules and biologics at GSK, J&J, Sanofi, Schering-Plough, Merck and Daiichi Sankyo. He was involved in the design and management of several pivotal clinical trials leading to approval and marketing of 5 blockbuster drugs, including the melanoma clinical trial of the PD-1 antibody Keytruda®. Dr. Zhang got his M.D. degree from Fudan University School of Medicine (formerly Shanghai First Medical College) and his Ph.D. degree from Temple University.